CHICAGO, Dec. 18, 2023 /PRNewswire/ -- Tissue Engineering Market in terms of revenue was estimated to be worth $4.4 billion in 2023 and is poised to reach $8.9 billion by 2028, growing at a CAGR of 15.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growing demand for innovative tissue engineering solutions for the treatment of chronic diseases and for repair and regeneration of tissues and technological developments such as 3D bioprinting is promoting the growth of the tissue engineering market.
Download an Illustrative overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34135173
Browse in-depth TOC on "Tissue Engineering Market"
364 - Tables
49 - Figures
358 - Pages
Tissue Engineering Market Scope:
Report Coverage |
Details |
Market Revenue in 2023 |
$4.4 billion |
Estimated Value by 2028 |
$8.9 billion |
Growth Rate |
Poised to grow at a CAGR of 15.3% |
Market Size Available for |
2021 - 2028 |
Forecast Period |
2023 - 2028 |
Forecast Units |
Value (USD Billion) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
Product Type, Material, Application, and End User |
Geographies Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa |
Report Highlights |
Updated financial information / product portfolio of players |
Key Market Opportunities |
Increasing technological advancements such as 3D printing and Quantum Magnetic Resonance Therapy (QMRT) |
Key Market Drivers |
Growing need for regenerative medicines |
The scaffolds product type segment accounted for the largest share of the product type segment in the tissue engineering market in 2022.
Based on product type, the tissue engineering market has been segmented into scaffolds, tissue grafts, and other products. Tissue grafts are further categorized into allografts, autografts, xenografts, and synthetic grafts. In 2022, the scaffold segment accounted for the largest share of the tissue engineering market. Increasing research activities for the development of advanced solutions for the repair and reconstruction of damaged tissues and organs is driving the demand for scaffolds.
The synthetic material segment is expected to grow at a higher growth rate during the forecast period.
Based on material, the tissue engineering market has been differentiated into synthetic material and biologically derived material. The synthetic material segment holds a major market share and is expected to grow at a higher rate during the forecast period 2023-2028. This can be attributed to increasing demand for cost effective and advanced treatment solutions for tissue repair and regeneration. In addition, the increasing adoption of innovative cell therapies is promoting segment growth in the tissue engineering market.
The orthopedic and musculoskeletal disorders application segment accounted for the largest market share by application in the tissue engineering market in 2022.
By application, the tissue engineering market has been further categorized as cardiovascular diseases, dermatology & wound care, orthopedics & musculoskeletal disorders, dental disorders, and others. Orthopedics & musculoskeletal disorders accounted for the major market share of the tissue engineering market in 2022. The large share of this segment can be attributed to the increasing demand for high-quality advanced solutions for the treatment of bone diseases. The rising adoption of tissue engineering solutions for bone regeneration and tissue reconstruction is promoting the growth of the orthopedics & musculoskeletal disorders segment in the tissue engineering market.
The ambulatory surgical centers segment is expected to grow at a higher growth rate during the forecast period.
Based on end users, the tissue engineering market has been categorized into hospitals, specialty centers and clinics, and ambulatory surgical centers. The ambulatory surgical centers segment is expected to grow at a higher rate during the forecast period 2023-2028. Ambulatory surgical centers are also known as same-day surgery centers. The growing adoption of advanced surgical technologies and the rising need for less time-consuming surgical processes is promoting the growth of the ambulatory surgical centers segment in the tissue engineering market.
The North American region catered for the largest share of the tissue engineering market in 2022.
The tissue engineering market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). The rising research activities and technological advancements in the medical sector in the North American region are the major driving factors for the growth of the tissue engineering market. Additionally, increasing investments and funding for the development of innovative cell therapies for the treatment of degenerative diseases is promoting the growth of the tissue engineering market in the North America region.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=34135173
Tissue Engineering Market Dynamics:
Drivers:
1. Growing need for regenerative medicines
Restraints:
1. High treatment cost
Opportunities:
1. Increasing technological advancements such as 3D printing and Quantum Magnetic Resonance Therapy (QMRT)
Challenge:
1. Cost effective traditional organ transplant techniques
Key Market Players of Tissue Engineering Industry:
Key players in the tissue engineering market include Organogenesis (US), AbbVie Inc. (US), Baxter (US), BD (US), B. Braun (Germany), TEIJIN Limited (Japan), Institut Straumann AG (Switzerland), Integra Lifesciences (US), Johnson & Johnson Services, Inc. (US), Medtronic (Ireland), NuVasive, Inc. (US), Stryker (US), Terumo Corporation (Japan), W. L. Gore & Associates Inc. (US), Zimmer Biomet (US), Smith & Nephew plc (UK), MIMEDX Group, Inc. (US), BioTissue (US), CollPlant Biotechnologies Ltd. (Israel), Sumitomo Pharma Co., Ltd. (Japan), Matricel GmbH (Germany), Mallinckrodt (US), Regrow Biosciences Pvt Ltd (India), Vericel Corporation (US), Tecnoss S.R.L. (Italy), Tegoscience (South Korea), and Tissue Regenix (UK).
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 80% and Demand Side 20%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%
Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=34135173
Recent Developments:
- In September 2023, MIMEDX Group Inc. launched EPIEFFECT to broaden its advanced wound care product portfolio. EPIEFFECT is a lyophilized human placental-based allograft consisting of amnion and chorion membranes.
- In July 2023, Teijin Limited launched SYNFOLIUM, a cardiovascular surgical patch and received manufacturing and marketing approval in Japan. The cardiovascular surgical patch is used for the surgical treatment of congenital heart disease (CHD).
- In July 2021, Integra Lifesciences introduced SurgiMend, a collagen matrix. The product is used for soft tissue repair and reconstruction.
- In May 2020, AbbVie Inc. (US) acquired Allergan plc (Ireland) to expand the product portfolio in therapeutics categories. Allergan plc provides new growth opportunities to AbbVie Inc. in neuroscience with Vraylar, Botox therapeutics, and global aesthetics business.
Tissue Engineering Market - Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall tissue engineering market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising funding and investments for the development of innovative tissue engineering products and growing need for tissue engineering solutions), restraints (strict regulations), opportunities (increasing technological advancements such as 3D bioprinting and organ-on-chip technology), and challenges (limited awareness for tissue engineering) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the tissue engineering market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tissue engineering market
- Competitive Assessment: Organogenesis (US), AbbVie Inc. (US), Baxter (US), BD (US), B. Braun (Germany), TEIJIN Limited (Japan), Institut Straumann AG (Switzerland), Integra Lifesciences (US), Johnson & Johnson Services, Inc. (US), Medtronic (Ireland), NuVasive, Inc. (US), Stryker (US), Terumo Corporation (Japan), W. L. Gore & Associates Inc. (US), Zimmer Biomet (US), Smith & Nephew plc (UK), MIMEDX Group, Inc. (US), BioTissue (US), CollPlant Biotechnologies Ltd. (Israel), Sumitomo Pharma Co., Ltd. (Japan), Matricel GmbH (Germany), Mallinckrodt (US), Regrow Biosciences Pvt Ltd (India), Vericel Corporation (US), Tecnoss S.R.L. (Italy), Tegoscience (South Korea), and Tissue Regenix (UK).
Related Reports:
Cartilage Repair Market - Global Forecasts to 2028
Flow Cytometry Market - Global Forecasts to 2028
Cell Therapy Technologies Market - Global Forecasts to 2028
Cell Culture Media Market - Global Forecasts to 2028
3D Cell Culture Market - Global Forecasts to 2028
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
22.50 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/tissue-engineering-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/tissue-engineering.asp
Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg
SOURCE MarketsandMarkets
![](https://rt.prnewswire.com/rt.gif?NewsItemId=IO96027&Transmission_Id=202312181030PR_NEWS_USPR_____IO96027&DateId=20231218)
Share this article